Latest News and Press Releases

This press release is not intended for UK media.  HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 75% (N=71), as demonstrated in the Beamion-LUNG 1 clinical...

CT-155 showed a reduction in experiential negative symptoms as an adjunct to standard of care antipsychotic therapy from baseline to week 16, as measured by CAINS-MAP.CT-155 is an investigational...

Boehringer and Re-Vana enter strategic collaboration to develop extended-release eye therapies, aiming to reduce injections and improve patient outcomes.

First half of 2025: Solid growth, investments and pipeline progress pave the way for two key launches in H2

Boehringer Ingelheim initiates Phase II study of BI 1815368, a potential first-in-class oral treatment for diabetic macular edema

A novel canine-specific detection algorithm is designed to improve early identification of heart disease and expand access to life-extending cardiac care for dogsIngelheim, Germany, and San Francisco,...

Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials atASCO

Nerandomilast, an investigational agent, met the primary endpoint of both phase III trials, FIBRONEER™-IPF and FIBRONEER™-ILD, significantly reducing the decline in forced vital capacity (FVC) [mL] by...

Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy.

Ingelheim, Germany, Oxford and Belfast, UK, April 29, 2025 – Boehringer Ingelheim, the University of Oxford, and Cumulus Neuroscience are joining forces to provide insights into the day-to-day...